Swaminathan et al. in 2021 hypothesized that the combination therapy of quizartinib plus either azacitidine or low-dose cytarabine may improve the outcomes in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-mutated AML. Here, FLT3 is linked to acute myeloid leukemia.